BET inhibitors have also been shown to be preferentially cytotoxic in the mutant BRCA2 context in both breast cancer and pan-cancer settings in a publicly available database for Genomics of Drug Sensitivity in Cancer [83,84]. This evidence concerns the gene BRCA2 and breast carcinoma.